全球麻疹、腮腺炎和风疹疫苗市场 – 行业趋势和 2028 年预测

市场分析和见解：全球麻疹、腮腺炎和风疹疫苗市场

预计全球麻疹、腮腺炎和风疹疫苗市场将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在上述研究预测期内，市场复合年增长率为 7.00%。新兴市场以及公共和政府部门对研发的巨额投资是推动该市场增长的因素。

肺炎球菌感染发病率不断上升，针对更多疾病开发联合疫苗的研究和研究也不断增加，联合疫苗的便利性也促进了市场增长，为市场提供了增长机会。此外，对此类制剂的需求不断增长、医务人员的偏好不断增加以及物流限制的减少都是市场增长的驱动因素。然而，严格的监管政策、潜在的副作用和生物恐怖主义的威胁可能会阻碍麻疹、腮腺炎和风疹疫苗市场的发展。

Vaccines for measles, mumps and rubella can either be administered individually or in combination. Combination vaccines are a mixture of two or more vaccines that can be administered individually into a single vaccine shot. This allows individuals to get fewer shots to get benefited for more number of diseases, easing the process for both the patients and the administrators with the administration of a single shot. Therefore, combinational shots for measles, mumps and rubella vaccines (MMR vaccines) market has an advantage over individual vaccines, moreover, partnerships of manufacturers with organizations such as UNICEF (United Nations Children's Fund) and WHO (World Health Organization) also act as drivers for the market. However, even when there have been fewer side effects, the concern for potential side effects and high prices may act as an opportunity to the individual segment and a restraint to combination segment of the market. Moreover, complex processes of studies and preparation leading to comparatively high prices of combination vaccines in most of the regions globally are expected to be a major challenge and restrict the growth combination segment of the market, however, as individual vaccines cost less (less than 1 USD for measles vaccines), individual shots may increase the market in underdeveloped and developing countries during the forecast period.

This measles, mumps and rubella vaccines market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Measles, Mumps and Rubella Vaccines Market Scope and Market Size

The measles, mumps and rubella vaccines market is segmented on the basis of type, age, disease type and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the measles, mumps and rubella vaccines market can be segmented into mono vaccines, combination vaccines.
• On the basis of age, the measles, mumps and rubella vaccines market can be segmented into children, adults. Age groups of children can be sub-segmented by immunization schedule into 12-15 months and 4-6 years.    
• On the basis of disease type, the measles, mumps and rubella vaccines market can be segmented into measles, mumps, and rubella.
• On the basis of distribution channel, the measles, mumps and rubella vaccines market can be segmented into hospital pharmacies, retailer pharmacies, others. 

Measles, Mumps and Rubella Vaccines Market Country Level Analysis

Measles, mumps and rubella vaccines market is analyzed and Market size information is provided by country, type, age, disease type and distribution channel as referenced above.   

The countries covered in the measles, mumps and rubella vaccines market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)..

On geographical estimation, America and Europe are experiencing tremendous growth due to the increasing number of research and development activities, technological advancements, financial stability among a major portion of general population, active support from government and private sectors and increasing the awareness of measles, mumps and rubella (MMR) vaccines. Asia-Pacific is estimated as the fastest growing Market during the forecast period due to increasing financial support and high rates of increase in population and therefore, increasing number of children as in most of the cases, measles, mumps and rubella vaccines are administered to children. Moreover, preference over individual vaccines for the ease in supply chain among distribution channels and for ease of hassle for administrators and patients, and major biotechnological advancements in countries such as Japan, South Korea, China and others are a major source for new research and developments for both individual and combination segments. However, comparatively lower financial advancement in these regions can be a potential threat to the growth of the market for combination segment, whereas, may act as an opportunity for individual vaccines segment.

麻疹、腮腺炎和风疹疫苗市场报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。

患者流行病学分析

麻疹、腮腺炎和风疹疫苗市场还为您提供有关患者使用情况和副作用的详细市场分析。麻疹、腮腺炎和风疹疫苗市场用于各种疾病的比率和时间表是报告中可用的一些数据变量。分析流行病学对市场增长的直接或间接影响，以创建更稳健和队列多元统计模型，用于预测增长期的市场。

竞争格局和麻疹、腮腺炎和风疹疫苗市场份额分析

麻疹、腮腺炎和风疹疫苗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、公司优势和劣势、产品发布、临床试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对麻疹、腮腺炎和风疹疫苗市场的关注有关。

麻疹、腮腺炎和风疹疫苗市场的主要参与者包括中国生物技术集团有限公司 (CNBG)、默克公司、MedImmune Health、JC Green Cannabis inc.、Bavarian Nordic、赛诺菲、辉瑞公司、诺华公司、强生服务公司、Emergent BioSolutions Inc.、葛兰素史克公司、CSL Limited、安斯泰来制药公司、CAVAC、KAKETSUKEN、京都医疗实验室、共立药业、GREENCROSS VETS 和印度血清研究所私人有限公司等国内外参与者。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。

SKU-59961